Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABBR2 | O75899 | 1/20 | 0.48 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.48 |
| ▸ | CYP26A1 | O43174 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 3/20 | 0.44 |
| ▸ | MIF | P14174 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | CPA1 | P15085 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | CPB1 | P15086 | 1/20 | 0.40 |
| ▸ | CPA3 | P15088 | 1/20 | 0.40 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.40 |
| ▸ | FNTA | P49354 | 1/20 | 0.38 |
| ▸ | FNTB | P49356 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30437060 | 1.00 | GABBR2 (0.48) | GABBR2GABBR1CYP26A1HTTMIF | |
| SCHEMBL657210 | 0.90 | GABBR2 (0.41) | GABBR2GABBR1CYP26A1HTTMIF | |
| SCHEMBL7763294 | 0.84 | CYP1A2 (0.46) | GABBR2GABBR1CYP26A1HTTCPA1 | |
| SCHEMBL7763289 | 0.84 | CYP1A2 (0.46) | GABBR2GABBR1CYP26A1HTTCPA1 | |
| SCHEMBL8771210 | 0.82 | SLC18A3 (0.46) | GABBR2GABBR1CYP26A1HTTCPA1 | |
| SCHEMBL27809268 | 0.82 | CYP26A1 (0.44) | GABBR2GABBR1CYP26A1HTTCPA1 | |
| SCHEMBL11072796 | 0.82 | HTT (0.42) | GABBR2GABBR1CYP26A1HTTPOLB | |
| SCHEMBL1613850 | 0.81 | HTT (0.49) | GABBR2GABBR1CYP26A1HTTL3MBTL1 | |
| SCHEMBL5720930 | 0.81 | CYP26A1 (0.46) | GABBR2GABBR1CYP26A1HTTCPA1 | |
| SCHEMBL31295224 | 0.81 | CYP26A1 (0.46) | GABBR2GABBR1CYP26A1HTTCPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3784655-B1 | PROCESS FOR PREPARING 2-(1-(TERT-BUTOXYCARBONYL)PIPERIDINE-4-YL)BENZOIC ACID | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-10-04 | — | — | EP | disclosed |
| EP-3784655-B1 | PROCESS FOR PREPARING 2-(1-(TERT-BUTOXYCARBONYL)PIPERIDINE-4-YL)BENZOIC ACID | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-10-04 | — | — | EP | disclosed |
| CN-112204007-B | Process for preparing 2- (1- (tert-butoxycarbonyl) piperidin-4-yl) benzoic acid | 施万生物制药研发IP有限责任公司 | 2023-06-20 | — | — | CN | disclosed |
| EP-3784655-A1 | PROCESS FOR PREPARING 2-(1-(TERT-BUTOXYCARBONYL)PIPERIDINE-4-YL)BENZOIC ACID | Theravance Biopharma R&D IP, LLC (US) | 2021-03-03 | — | — | EP | disclosed |
| CN-112204007-A | Process for the preparation of 2- (1- (tert-butoxycarbonyl) piperidin-4-yl) benzoic acid | 施万生物制药研发IP有限责任公司 | 2021-01-08 | — | — | CN | disclosed |
| US-10640467-B2 | Process for preparing 2-(1-(tert-butoxycarbonyl)piperidine-4-yl)benzoic acid | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-05-05 | — | — | US | disclosed |
| US-10640467-B2 | Process for preparing 2-(1-(tert-butoxycarbonyl)piperidine-4-yl)benzoic acid | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-05-05 | — | — | US | disclosed |
| EP-2349999-B1 | ALLOSTERIC PROTEIN KINASE MODULATORS | UNIV SAARLAND (DE) | 2016-01-27 | — | — | EP | disclosed |
| US-8912186-B2 | Allosteric protein kinase modulators | UNIVERSITAET DES SAARLANDES (DE) | 2014-12-16 | — | — | US | disclosed |
| US-20120046307-A1 | ALLOSTERIC PROTEIN KINASE MODULATORS | UNIVERSITAET DES SAARLANDES (DE) | 2012-02-23 | — | — | US | disclosed |
| EP-2349999-A1 | ALLOSTERIC PROTEIN KINASE MODULATORS | Universität des Saarlandes (DE) | 2011-08-03 | — | — | EP | disclosed |
| WO-2010043711-A1 | ALLOSTERIC PROTEIN KINASE MODULATORS | UNIVERSITAET DES SAARLANDES (DE) | 2010-04-22 | — | — | WO | disclosed |
| EP-2177510-A1 | Allosteric protein kinase modulators | Universität des Saarlandes (DE) | 2010-04-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10640467-B2 | Process for preparing 2-(1-(tert-butoxycarbonyl)piperidine-4-yl)benzoic acid | BDNF, GABRE, NPY5R | GABBR2 10/4885GABBR1 7/4885CYP26A1 189/4885 |
| US-20120046307-A1 | ALLOSTERIC PROTEIN KINASE MODULATORS | AURKC, AURKA, AURKB | GABBR2 4480/4885GABBR1 4561/4885CYP26A1 4700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.